01:28 AM EDT, 09/18/2026 (MT Newswires) -- Sandoz Group (SDZ.SW) said Friday that Health Canada granted marketing authorization for its GLP-1 receptor agonist injection, Sandoz Semaglutide, for adult patients with type 2 diabetes mellitus. Semaglutide, a generic version of Novo Nordisk's (NOVO-B.CO) Ozempic, was approved for once-weekly subcutaneous injection. It will be available in three dose strengths delivered via two pen presentations. The approval follows the recent US Food and Drug Administration acceptance of the company's applications for in-house development of generic tirzepatide GLP-1s and the approval of Owozy, semaglutide, in Brazil, for which Sandoz has commercial rights.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.